Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors

This publication has 57 references indexed in Scilit:

• Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
  Nature, 2007
• Quantification of endocannabinoids in rat biological samples by GC/MS: Technical and theoretical considerations
  Prostaglandins & Other Lipid Mediators, 2006
• A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats
  Neuropharmacology, 2006
• The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin
  Proceedings of the National Academy of Sciences, 2006
• Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
  Experimental Neurology, 2006
• A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease
  The FASEB Journal, 2005
• Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
  Experimental Neurology, 2002
• Oxidative metabolism of endocannabinoids
  Prostaglandins, Leukotrienes & Essential Fatty Acids, 2002
• The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway
  Brain Research, 1995
• The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons
  Life Sciences, 1995